IFNGR1 and acute lymphoblastic leukemia: Using a fluorescence-based competition assay comparing the relative growth of mixtures of isogenic knock out or control B-ALL cells in vitro and in vivo, we found that the proportion of cells null for Ifngr1, Jak2, or Stat1 significantly depleted in both the bone marrow and spleens of mice treated with anti-mCD19 CAR-T therapy (Fig. 3b, c showing log-scale depletion).